Lilly Reports Negative Results of Solanezumab in P-III EXPEDITION Studies in Patients with Alzheimer Disease

 Lilly Reports Negative Results of Solanezumab in P-III EXPEDITION Studies in Patients with Alzheimer Disease

Lilly Reports Negative Results of Solanezumab in P-III EXPEDITION Studies in Patients with Alzheimer Disease

Shots:

  • The P-III EXPEDITION Study involves assessing of Solanezumab (400 mg, IV, q4w) vs PBO in 1,012 (EXPEDITION1) & 1,040 (EXPEDITION2) patients with mild or mild to moderate Alzheimer disease
  • The study resulted in unmet endpoint and demonstrated 42% reduction in decline, 20% reduction in cognitive decline, 19 percent reduction in functional decline in patients
  • Solanezumab is a monoclonal IgG1 Ab, evaluated as a neuroprotector in patients with Alzheimer disease

Click here read full press release/ article | Ref: Eli Lilly | Image: The Street


Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post